出典: meddic

arabinofuranosylcytosinecytarabinecytarabine hydrochloridecytarabine ocfosphatecytosine arabinoside

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells.
  • Cui XY, Skretting G, Jing Y, Sun H, Sandset PM, Sun L.SourceDepartment of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Stem Cell Research Center, Zhengzhou University, Zhengzhou, China; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway. Electronic address:
  • Blood cells, molecules & diseases.Blood Cells Mol Dis.2013 Oct;51(3):177-84. doi: 10.1016/j.bcmd.2013.05.003. Epub 2013 May 29.
  • OBJECTIVES: The present study investigates the potential role of hypoxia in maintaining stem cell-like properties and therapeutic resistance in K562 leukemic cell.METHODS: Western blot, flow cytometry and cell viability assays were used to investigate the effects of hypoxia (1% O2) on cell prolifera
  • PMID 23725749
  • Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.
  • Momparler RL.AbstractCytarabine (cytosine arabinoside) is one of the most effective drugs for the treatment of acute myeloid leukemia. The standard dose of cytarabine used to treat this leukemia is 100 mg per square meter. In an attempt to improve the effectiveness of cytarabine against acute myeloid leukemia, a high-dose treatment (3,000 mg per square meter) was introduced into therapy. The side effects of high-dose cytarabine was a major concern, especially its neurological toxicity. A review of recent clinical trials indicates that this high-dose cytarabine can be replaced by the intermediate-dose of 1,000 mg per square meter without loss of efficacy and with less toxicity. This is an important step to improve the efficacy of cytarabine for the treatment of acute myeloid leukemia. Despite the improvements in the therapy for this leukemia, the current overall survival rate for adult patients is less than 30%. To optimize the cytarabine therapy, it is important to determine how some leukemic stem cells survive treatment. Preclinical data suggest that survival of the leukemic stem cells could be due to the long 12 hour interval between infusions of cytarabine, which permits some leukemic cells to escape its S phase specific action. Among the other factors that can lead to leukemic cell survival are the high levels in the liver and spleen of cytidine deaminase, the enzyme that inactivates cytarabine and drug resistance due to deficiency in deoxycytidine kinase, the enzyme that activates the prodrug, cytarabine. Several approaches are proposed in this commentary to overcome these impediments with the goal of increasing the effectiveness of cytarabine for the treatment of acute myeloid leukemia.
  • Experimental hematology & oncology.Exp Hematol Oncol.2013 Aug 6;2(1):20. [Epub ahead of print]
  • Cytarabine (cytosine arabinoside) is one of the most effective drugs for the treatment of acute myeloid leukemia. The standard dose of cytarabine used to treat this leukemia is 100 mg per square meter. In an attempt to improve the effectiveness of cytarabine against acute myeloid leukemia, a high-do
  • PMID 23919448
  • Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia.
  • Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Chen YB, Neuberg DS, Fathi AT.SourceDepartment of Hematology and Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts.
  • American journal of hematology.Am J Hematol.2013 Aug;88(8):642-6. doi: 10.1002/ajh.23462. Epub 2013 May 30.
  • Acute myeloid leukemia (AML) is more common and more lethal among patients over the age of 60. Increased body mass index (BMI) has been associated with a higher incidence of various malignancies, including AML. We sought to determine whether patient BMI at the time of AML diagnosis is related to ove
  • PMID 23619915



Generic name: Cytarabine Trade names: Cytosar-U® Other names: Ara-C, Arabinosylcytosine uses generic names in all descriptions of drugs. Cytosar-U is the trade name for Cytarabine. Ara-C and ...
オーダーメイド.リフォーム,結婚・婚約指輪、名古屋市(天白区・緑区・名東区)、マリッジリングといったブライダル中心に製作しています。 ダイヤ等から、ペンダント・ピアス等に加工します。彫金教室、豊田市〜近郊・岡崎市 ...



先読みcytarabine ocfosphate」「cytosine arabinoside
リンク元シタラビン」「cytarabine hydrochloride」「シトシンアラビノシド」「アラビノフラノシルシトシン」「arabinofuranosylcytosine

cytarabine ocfosphate」

  [★] シタラビンシタラビンオクホスファート

cytosine arabinoside」

  [★] シトシンアラビノシドシタラビン



cytarabine,Ara-C, ara-C
シトシンアラビノシド cytosine arabinosideアラビノシルシトシン arabinosylcytosine
シタラビンオクホスファート cytarabine ocfosphate塩酸シタラビン cytarabine hydrochloride
キロサイドスタラシドサイトサール CytosarTarabine
cytarabine HC1代謝拮抗剤




  • キロサイドN注400mg/**キロサイドN注1g

cytarabine hydrochloride」


ara-Carabinofuranosylcytosinecytarabinecytarabine ocfosphatecytosine arabinoside



cytosine arabinosideara-C







ara-Ccytarabinecytarabine hydrochloridecytosine arabinoside



WordNet   license wordnet

「the 3rd letter of the Roman alphabet」

WordNet   license wordnet

「(music) the keynote of the scale of C major」

WordNet   license wordnet

「a general-purpose programing language closely associated with the UNIX operating system」

PrepTutorEJDIC   license prepejdic




WordNet   license wordnet

genus Ara

WordNet   license wordnet

「a constellation in the southern hemisphere near Telescopium and Norma」


  [★] セシウム, caesium, cesium

PrepTutorEJDIC   license prepejdic



  [★] カドミウム


PrepTutorEJDIC   license prepejdic




PrepTutorEJDIC   license prepejdic

「are (面積の単位)の変形」

"" より作成